Phase 3Terminated
Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation (CONVINCE)
Multicenter, Randomized Study Comparing Oral Valganciclovir Versus Intravenous Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
- Sponsor
- Pierrel Research Europe GmbH (Industry)
- Enrollment
- 212 planned
- Conditions
- Allogeneic Stem Cell Transplantation
- Interventions
- Valganciclovir; Ganciclovir
- Ages
- adults, older adults
- Registry
- NCT01185223
Full record on ClinicalTrials.gov
From the registry
The objective of this study is to assess the efficacy and safety of oral valganciclovir versus intravenous ganciclovir in patients following allogenic stem cell transplantation.
Primary outcomes
- Efficacy and Safety of oral valganciclovir versus intravenous ganciclovir
History
Primary completion
Last registry update
Started
Registered